Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. - Wikidata - awgldk - TriplyDB

Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention.

Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention.

http://www.wikidata.org/entity/Q36344699

about

Whole-Body Vibration as a Modality for the Rehabilitation of Peripheral Neuropathies: Implications for Cancer Survivors Suffering from Chemotherapy-Induced Peripheral Neuropathy Mechanisms involved in the development of chemotherapy-induced neuropathy Peripheral neuropathy due to vitamin deficiency, toxins, and medications Therapeutic Effects of Phytochemicals and Medicinal Herbs on Chemotherapy-Induced Peripheral Neuropathy Bortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouse Lifestyle-Related Factors in the Self-Management of Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer: A Systematic Review.Subcutaneous testosterone-letrozole therapy before and concurrent with neoadjuvant breast chemotherapy: clinical response and therapeutic implications The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials The G2A receptor (GPR132) contributes to oxaliplatin-induced mechanical pain hypersensitivity.Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study.Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy.[EXPRESS] Ion channels and neuronal hyperexcitability in chemotherapy-induced peripheral neuropathy; cause and effect?Development of TRPM8 Antagonists to Treat Chronic Pain and Migraine.Mangafodipir a Selective Cytoprotectant - with Special Reference to Oxaliplatin and Its Association to Chemotherapy-Induced Peripheral Neuropathy (CIPN)Oxaliplatin neurotoxicity involves peroxisome alterations. PPARγ agonism as preventive pharmacological approach.Increased spinal cord Na⁺-K⁺-2Cl⁻ cotransporter-1 (NKCC1) activity contributes to impairment of synaptic inhibition in paclitaxel-induced neuropathic pain Amelioration of cisplatin-induced experimental peripheral neuropathy by a small molecule targeting p75 NTR Platinum-induced neurotoxicity and preventive strategies: past, present, and future New tools for the quantitative assessment of prodrug delivery and neurotoxicity.Urinary N telopeptide levels in predicting the anti-nociceptive responses of zoledronic acid and paclitaxel in a rat model of bone metastases.Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics.Multiple impairments of cutaneous nociceptor function induced by cardiotoxic doses of Adriamycin in the rat.Low Levels of NDRG1 in Nerve Tissue Are Predictive of Severe Paclitaxel-Induced Neuropathy.Chemotherapy-induced peripheral neuropathy: Current status and progress.Pharmacological comparison of a nonhuman primate and a rat model of oxaliplatin-induced neuropathic cold hypersensitivity.Neurotoxicity to DRG neurons varies between rodent strains treated with cisplatin and bortezomib.Long-term Toxicity of Cancer Treatment in Older Patients Significance of Kampo, traditional Japanese medicine, in supportive care of cancer patients Urothelial carcinoma management in elderly or unfit patients.Dorsal Root Ganglion Infiltration by Macrophages Contributes to Paclitaxel Chemotherapy-Induced Peripheral Neuropathy Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma.Clinical study on the prevention of oxaliplatin-induced neurotoxicity with guilongtongluofang: results of a randomized, double-blind, placebo-controlled trial.Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin.Magnetic field therapy in patients with cytostatics-induced polyneuropathy: A prospective randomized placebo-controlled phase-III study Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature.Minoxidil is a potential neuroprotective drug for paclitaxel-induced peripheral neuropathy.Electrophysiological, behavioral and histological characterization of paclitaxel, cisplatin, vincristine and bortezomib-induced neuropathy in C57Bl/6 mice.Brief review: chemotherapy-induced painful peripheral neuropathy (CIPPN): current status and future directions.Chemotherapy-induced peripheral neurotoxicity (CIPN): what we need and what we know.Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review.

P2860

Q26771423-A0417B48-199C-400F-9DF7-EC31C3DBBB4F Q26824380-F1B2F5D3-73F6-4EEE-9B3C-90839EA37CB7 Q27026245-9F06B16C-7153-49A9-AAB9-5700500D68F6 Q28075341-271281BB-DC43-4D55-B853-D0C8BACFB0E2 Q28533426-729BF4A5-3584-4044-95BF-A7E810C59936 Q30234847-5F5F5BC2-9B14-4D77-97F2-483FE6979439 Q30490897-9BA92979-9C68-4B7E-8F46-9E0F826CBE9C Q33409319-71B50DB2-4609-4E9C-A80A-83BBBD7E416E Q33672384-0A978ED4-707B-40B9-AC37-FD6776A92A67 Q33684190-464CA439-A7ED-41CA-82A8-212EC4558664 Q33744706-01970B06-D01A-4533-BDE3-11E66A1AAC2D Q33824948-6238622E-543D-41D6-B2FB-B511A7B9928E Q33851503-C05F2539-FC80-4BF6-A9D5-680CF8F570DF Q33868520-3E3C8A33-9F60-4462-8EC6-009C281BFC1B Q33921641-E1EE6D2C-2547-4E76-B7A0-8030D503C375 Q34467512-3CBB3CBE-0BFE-4574-833A-CA4F217B72C8 Q34717624-B3F08B32-0C0D-4C6D-8C49-E5D3BE7E9D4C Q35345734-2B67CC41-6DE7-465C-8441-52D5AFEDEA1D Q35849165-3A788776-650B-4E1F-AD8B-D38DD80ED868 Q35919801-07EDF10F-8EAC-4882-9A69-BAA90BC6E8F4 Q36057728-DA12B933-F655-41DF-8D46-AD97BBB47CDD Q36061374-D6E08FB2-4B98-4C4C-A260-F68D910E1B9E Q36157639-04ABCE08-C06D-4C7A-8B55-571B5868256B Q36421901-E078B594-3B3F-426D-AB85-153620A0D26D Q36648880-BCEEB530-601D-4F5E-AFC5-5D321A9B46F7 Q36655166-3164B39F-6135-4337-9B0D-39AB3B5D11F6 Q36821673-6012A29B-D88B-48B9-B09D-F3BF0943FCB0 Q36990461-BF443D66-7667-4832-A7EC-1FA6B1698E2E Q37030514-654CA23D-845A-4815-BD6D-C3F1E25B4E76 Q37081502-F79E1F87-723A-47F4-BB59-473C717D53D4 Q37274320-AD5846E9-5359-4A85-8399-F8C964A6872C Q37353630-CC836AA7-F924-4C6B-9B32-6F5C1E9A77DA Q37404101-9311D085-0FEB-43B1-B9CD-C8F64873B0CD Q37595960-610F62D4-E64E-46F1-8A98-6BDAE6C975B9 Q37659699-EB365B19-073C-4D4B-ACFF-B93E8F5DF2F2 Q37724339-BD714355-B015-4923-920B-FBA28769179A Q37734620-C2370032-E152-45E1-AD8D-0995B75006C4 Q38209959-B2F20289-7FAC-486F-890F-DF2315B730D4 Q38224422-936DC20F-058E-460F-AB41-E9B5E1B22517 Q38254351-6AB897FB-4FAA-4EC8-B3F0-E125A9E6B099

P2860

Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention.

http://www.wikidata.org/entity/Q36344699

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Peripheral neuropathies from c ...... is, treatment, and prevention.

@ast

Peripheral neuropathies from c ...... is, treatment, and prevention.

@en

type

label

Peripheral neuropathies from c ...... is, treatment, and prevention.

@ast

Peripheral neuropathies from c ...... is, treatment, and prevention.

@en

prefLabel

Peripheral neuropathies from c ...... is, treatment, and prevention.

@ast

Peripheral neuropathies from c ...... is, treatment, and prevention.

@en

P1433

Q36344699-809688F4-548E-46C6-A5F4-26C9ECF04871

P1476

Q36344699-11899B26-02A4-4A01-AA3D-183050B248F4

P2093

Q36344699-1441A9BF-98E8-4BAA-A10A-13A66EC3E9F0

Q36344699-CEA3223F-D61C-441B-B9B9-557B74ED5BB2

P2860

Q36344699-01EFE6CF-57B8-44B2-ABFD-DC93585A8B1A

Q36344699-039A050E-451A-474C-8A55-D22831B0BA0D

Q36344699-063EBD91-047A-4609-97E3-4A6FE80626B5

Q36344699-0D61CB92-73EE-45F6-A5DB-D3309E008F85

Q36344699-12E30721-14EC-421A-B2DE-AB477A422DE4

Q36344699-17EEFAD3-CDF3-4018-9E32-F939B062431E

Q36344699-18E0F4AF-3272-423D-83BB-58112A01239C

Q36344699-1A54608A-7A2C-44CE-86E7-D377478647A7

Q36344699-1BD57E7E-9B9B-46CB-BE2F-1F7BFB76A47C

Q36344699-1F1171F9-96EA-46CB-9A08-260EE62235C8

P304

Q36344699-24E761E9-6113-4E7F-AB83-D18F1FA9A008

P31

Q36344699-AF0E0D77-9EFA-4EB6-B297-1DAD998E0D2D

P356

Q36344699-1C44BDFA-CCDD-4238-9C2D-065B1A0EE5AA

P478

Q36344699-57B88052-D360-4405-AC03-AF6219B330DA

P50

Q36344699-A7835BE4-FB80-4254-B411-A6CF2F0B0C0A

P577

Q36344699-E3321197-B2C3-4D1F-9927-9477315D31B8

P5875

Q36344699-F70290C0-1DA4-410B-879A-9C0A501164BC

P698

Q36344699-03C70D24-6A24-48CC-A621-8C03E26A3C66

P921

Q36344699-9924A0B3-2DBC-4E46-B429-A4C95ADDB681

P932

Q36344699-A6CFA83F-2D69-4F35-8EF0-1C1E387AF4CE

P356

P1433

P1476

Peripheral neuropathies from c ...... is, treatment, and prevention.

@en

P2093

Anthony J Windebank

http://www.w3.org/2001/XMLSchema#string

Wolfgang Grisold

http://www.w3.org/2001/XMLSchema#string

P2860

Interventions for preventing neuropathy caused by cisplatin and related compounds

Cancer survivors in the United States: a review of the literature and a call to action

European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripher

Muscle cramps associated with vincristine therapy

Clinical and electrophysiological studies in vincristine induced neuropathy

Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer.

Carfilzomib: a novel second-generation proteasome inhibitor

Comparative adverse effect profiles of platinum drugs.

Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trials

Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.

P304

iv45-54

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NEUONC/NOS203

http://www.w3.org/2001/XMLSchema#string

P478

14 Suppl 4

http://www.w3.org/2001/XMLSchema#string

P50

Guido Cavaletti

P577

2012-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

274431304

http://www.w3.org/2001/XMLSchema#string

P698

23095830

http://www.w3.org/2001/XMLSchema#string

P921

P932

3480245

http://www.w3.org/2001/XMLSchema#string